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Abstract
Background: There still is no evidence which neoadjuvant therapy regimen for stage II–III rectal cancer is superior.
The aim of this study was to compare results achieved after long-course chemoradiotherapy (CRT) with short-term
radiotherapy (RT) followed by delayed surgery.
Methods: A randomized trial was carried out between 2007–2013. One hundred fifty patients diagnosed with stage
II–III rectal cancer were randomized into one of two neoadjuvant treatment arms: conventional chemoradiotherapy
(CRT) and short-term radiotherapy (RT) followed by surgery after 6–8 weeks. Primary endpoints of this trial were
downstaging and pathological complete response rate. Secondary endpoints were local recurrence rate and overall
survival.
Results: The pathological complete response was found in 3 (4.4%) cases after RT and 8 (11.1%) after CRT (P = 0.
112). Downstaging (stage 0 and I) was observed in 21 (30.9%) cases in RT group vs. 27 (37.5%) cases in CRT group
(P = 0.409). Median follow-up time was 39.7 (range 4.9–79.7) months. 3-years overall survival (OS) was 78% in RT
group vs. 82.4% in CRT group (P = 0.145), while disease-free survival (DFS) differed significantly – 59% in RT group
vs. 75.1% in CRT group (P = 0,022). Hazard ratio of cancer progression for RT patients was 1.93 (95% CI: 1.08–3.43)
compared to CRT patients.
Conclusion: Three-years disease-free survival was better in CRT group comparing with RT group with no difference
in overall survival.
Trial registration: http://clinicaltrials.gov identifier NCT00597311. January 2008.
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Background
Preoperative conventional chemoradiotherapy (25 ×
2 Gy + 5-Fu) with delayed surgery and short-term radio-
therapy (5 x5Gy) with immediate surgery are the most
common regimens of treatment, causing reduction of
local recurrence rate for patients with resectable rectal
cancer [1–7]. Two meta-analysis [8, 9] and review [10]
showed no differences between these regimens in terms
of survival, local recurrence, morbidity, mortality, resect-
ability and the rate of sphincter preservation; however,
pathological complete response and toxicity were higher
after neoadjuvant chemoradiation.
Radu et al. [11] were the first to present the hypothesis
that short-term radiotherapy and delayed surgery could
give similar results as conventional CRT. Stockholm III
trial reported similar results of complete response, rate of
complications and toxicity after preoperative long-course
or short-course radiotherapy with delayed surgery [12].
The approach of short-term radiotherapy with delayed
surgery has also been evaluated in prospective randomized
trial (http://clinicaltrials.gov identifier: NCT00597311)
which was carried out between 2007–2013 in the Hospital
of Lithuanian University of Health Sciences. Comparison
was mainly based on the rates of downstaging after short-
term radiotherapy or conventional chemoradiotherapy
followed by surgery after 6–8 weeks. Initial results of
this trial including the first 83 patients were published
previously in 2012 [13]. This is a secondary evaluation
of the treatment arms including the same 83 and the
total required 150 patients.
Methods
The study was approved by Kaunas Regional Committee
of Ethics of Biomedical Research (Protocol No. 137⁄2006).
The inclusion, exclusion criteria and initial results have
been reported previously [13]. Completely informed con-
sent was obtained from the patients. Digital examination,
endoscopy with biopsy, chest X-ray, abdominal ultrasound
and blood analysis were performed. T and N stages were
assessed using endorectal ultrasound (ERUS), pelvic com-
puterized tomography (CT) and magnetic resonance im-
aging (MRI) and patients with resectable stage II or III
(T3 N0, T4 N0, Tx N+) rectal cancer were included and
blindly randomized into one of the two arms. ERUS, pelvic
CT and MRI were repeated before the surgery for re-
evaluation of T and N stage and maximal wall thickness.
The investigator was not blinded to the pre-treatment
ERUS results. The problem of clinical staging was that
ERUS was not technically possible for all patients because
of localization and size of the tumor and MRI was not
made for the first 40 patients.
One hundred fifty patients diagnosed with resectable
stage II or III rectal cancer were randomized to two neoad-
juvant treatment arms: conventional chemoradiotherapy
(CRT; 50 Gy in total administered during a period of
5 weeks, 2 Gy per fraction and two cycles of 5-FU/
Leucovarin, 400 mg/m2 of 5-fluorouracil i/v in com-
bination with leucovorin 20 mg/m2 i/v for 1–4 days
on the first and on the fifth week) and short-term
radiotherapy (RT; 5 fractions of radiotherapy, 5 Gy per
fraction, administered each day for 5 days, a dose of
25 Gy in total). Patients were assessed with respect of
possible adverse effects of neoadjuvant treatment,
along with filling QLQ questionnaires. Data regarding
toxicity will be presented in another article.
Both groups underwent surgery in a period of 6 to
8 weeks after a termination of preoperative treatment.
Type of surgery was chosen depending on the site of
lesion in images of ERUS, pelvic CT and MRI, but final
decision was made during the surgery and it was one of
the following: abdominoperineal resection, Hartman’s pro-
cedure, proctectomy with coloanal anastomosis, or anter-
ior rectal resection. Surgery was performed by the same 6
surgeons specializing in coloproctology. Total mesorectal
excision was mandatory during surgery. Adjuvant Chemo-
therapy of 5-FU (400 mg/m2 i/v and Leucovorin (20 mg/
m2 i/v) 1–5 days for 4 cycles every 4 weeks was started
within 8 weeks after surgery.
Follow-up
Patients were examined every 3–6 months during the
first 2 years after surgery, and once per year for the fol-
lowing 5 years at least. Evaluation consisted of physical
examination, blood tests, abdominal ultrasound, chest
radiography and colonoscopy every 6–12 months. CT
and MRI were performed in cases of suspected local re-
currence or metastasis. No patient was lost during the
follow up.
Statistical analysis
The primary endpoint of this trial was downstaging and
pathological complete response rate. In order to calcu-
late the sample size it was assumed that the downstaging
rate after chemoradiotherapy would be 40%. To detect a
20% difference between the groups using the χ2 test and
a significance level of 0.05, the study should include 74
patients (37 patients in each group). Secondary end-
points were local recurrence and overall survival. Sec-
ondary endpoints analysis was planned to be performed
after recruitement of 150 patients. The χ2 test was used
for comparison of proportions and the Mann–Whitney
U test for comparison of continuous variables. Actuarial
curves were calculated by the Kaplan–Meier method
and were compared by the log rank test. The Cox’s pro-
portional hazards model was used to calculate the
hazard ratios and 95% confidence intervals (c.i.) in the
univariable analysis. All the tests were two sided. Calcu-
lation of time intervals was started from the date of
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randomization. Patients who had not undergone primary
tumour excision or who had distant metastases detected
before or during surgery were considered as treatment
failures at the time of randomization and were excluded
from the study. When calculating the rate of permanent
stoma, diverting stoma or stoma after Hartmann’s pro-
cedure were excluded, if stoma was reversed later.
Results
Amongst 150 randomly assigned patients 10 were ex-
cluded from the study due to protocol violation. All eli-
gible patients were included in the statistical analysis
(Fig. 1). Patients’ characteristics were similar between
the two treatment groups (Table 1).
Surgery
RT and CRT groups were comparable regarding the
type of surgery and morbidity. Results are presented
in Table 2.
Pathology
A histopathological complete response was found in 3
(4.4%) cases after RT and 8 (11.1%) after CRT (P =
0.112). Downstaging (stage 0 and I) was observed in 21
(30.9%) cases in RT group vs.27 (37.5%) cases in CRT
group (P = 0.409). There were more cases with early
Fig. 1 CONSORT diagram for patients randomized in the trial






Age (years) 65.6 (SD = 9.5) 63.14 (SD = 10.1) 0.141
Gender (%)
Male 43 (63.2) 50 (69.4) 0.437
Female 25 (36.8) 22 (30.6)
ASA1 (%) 1 (1.5) 1 (1.4)
ASA2 (%) 32 (48.5) 31 (43.1) 0.808
ASA3 (%) 33 (50) 40 (55.5)
Period from the end of
neoadjuvant therapy till
surgery (days)
48.03 (SD = 12.5) 47.14 (SD = 8.6) 0.622
Clinical stage (%)
II 16 (23.5) 15 (20.8) 0.701
III 52 (76.5) 57 (79.2)
Tumor distance from anal
verge (%)
< 5 cm 34 (50) 30 (41.7)
5–10 cm 29 (42.6) 37 (51.4) 0.575
11–15 cm 5 (7.4) 5 (6.9)
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pathological stage (pT0, pT1) in the CRT group and
more cases with pT3 disease in the RT group, however,
the difference was not statistically significant (P > 0.05).
The positive lymph-nodes were found in 25 (36.8%)
cases in the RT group and in 18 (25%) cases of CRT
group (P > 0.05). The majority of patients had a moder-
ately differentiated (G2) tumour (83.6% and 79.7% in the
RT and CRT groups, respectively). Groups were compar-
able in terms of circumferential and distal margin, tumor
size, vascular and lymphatic invasion (Table 3).
Long-term oncological results
Median follow-up time was 39.7 (range 4.9–79.7) months.
During the time of observation 31 patients had died: 17
(25%) in RT group and 14 (19.4%) in CRT group (P > 0.05).
Hazard ratio of death for RT patients compared to patients
in CRT group was 1.64 (95% CI: 0.8–3.43). Cancer progres-
sion was observed in 16 (25%) cases in RT group vs. 13
(18.3%) cases in CRT group (P > 0.05). The rate of local re-
currence between the groups was: 2 (3.1%) cases in RT
group vs. 4 (5.6%) in CRT group (P > 0.05). During the
follow-up distant metastases developed in 14 (21.9%) cases
after RT and in 9 (12.7%) cases after CRT (P > 0.05). Hazard
ratio of distant metastases for RT patients compared to
CRT patients was 2.2 (95% CI: 0.95–5.10). Causes of death
and cancer progression are summarized in Table 4.
Three- years OS was 78% in RT group vs. 82.4% in
CRT group (P = 0,145), while DFS was 59% in RT group
vs. 75.1% in CRT group (P = 0,022) (Fig. 2). Hazard ratio
of cancer progression (distant and local) for RT patients
compared to CRT patients was 1.93 (95% CI: 1.08–3.43).
Discussion
Currently there is no optimal neoadjuvant treatment
regimen for locally advanced rectal cancer yet. Accord-
ing to ESMO clinical practice guidelines of 2013, con-
ventionally fractionated chemoradiotherapy (25 × 2 Gy)
with delayed surgery or short-course radiotherapy (5 ×5
Gy) with surgery in 1 week for resectable rectal cancer
are recommended [14]. These recommendations are
based on the results of well known trials [1], but the
problem persists that these two treatment options are
quite different, resulting in different treatment policies
among countries or even specialists in the same country.
Two meta-analyses revealed no differences between
these regimens in terms of the rates of survival, local re-
currence, morbidity, mortality, resectability and the rate of
sphincter preservation, and only pathological complete
response and toxicity were higher after neoadjuvant







Radical surgery 57 (83.8) 64 (88.9) 0.382
Non-radical 11 (16.2) 8 (11.1)
Postive distal margin (R+) 2 0
Positive circumferential







10.06 (SD = 6.9) 9.15 (SD = 3.7) 0.355
Sphincter saving surgery 47 (69.1) 52 (72.2) 0.687
Permanent stoma 27 (39.7) 25 (34.7) 0.542
Defunctioning stoma 41 (60.3) 47 (65.3)
Anterior resection with
anastomosis
35 (51.5) 40 (55.6) 0.959
Proctectomy with coloanal
anastomosis
6 (8.8) 7 (9.7)
Hartman‘s procedure 6 (8.8) 5 (6.9)
Abdominoperineal resection 21 (30.9) 20 (27.8)
Complications 24 (35.3) 19 (26.8) 0.277
Anastomotic 4 (5.8) 5 (6.9)
Wound 7 (10.2) 6 (8.3)
Stoma 4 (5.8) 1 (1.4)
Intrasurgical 2 (3.3) 3 (4.3)
Other 7 (10.2) 4 (5.9)
Reoperations 1 (1.5) 4 (5.6) 0.235






ypT0 3 (4.4) 8 (11.1) 0.112
ypT1 3 (4.4) 5 (6.9)
ypT2 18 (26.5) 19 (26.4)
ypT3 44 (64.7) 36 (50)
ypT4 0 4 (5.6)
ypN0 43 (64.2) 54 (75) 0.318
ypN1 19 (27.9) 14 (19.4)
ypN2 6 (8.9) 4 (5.6)
Differentiation
G1 6 (9) 5 (7.8) 0.306
G2 56 (83.5) 51 (79.7)
G3 5 (7.5) 8 (12.5)
ypL1 (lymphatic) 23 (37.1) 22 (31.9) 0.530
ypV1 (vascular) 19 (31.1) 15 (21.7) 0.233
Distal resection
margin (mm) 29.83 (SD = 15.1) 31.62 (SD = 17.1) 0.538
Circumferential resection
margin (mm) 5.02 (SD = 4.44) 7 (SD = 7.19) 0.193
Tumor size (mm) 26.22 (SD = 12.22) 25.13 (SD = 12.48) 0.622
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chemotherapy [8, 9]. Bujko et al. compared neoadjuvant
short-course radiotherapy (RT) followed by surgery within
7 days with conventional long-course chemoradiotherapy
(CRT) and found that 4 years overall, disease-free survival
rates and local recurrence rate did not differ significantly
between the groups [6]. Complete response rate was
higher in CRT group: 16.1% vs 0.7%, tumor involvement
of the circumferential margin was 4% after chemoradio-
therapy vs 13% after short-course radiotherapy (P < 0.05),
but the toxicity (incidense of III-IV grade adverse effects)
rate was also significantly higher 18.2% vs 3.2% in CRT vs
RT group, respectively.
Retrospective data from Radu et al. showed that patho-
logical complete response and local disease control have
been similar between short-term radiotherapy with de-
layed surgery (6–8 weeks) and long-course chemoradio-
therapy, with low rates of toxicity in both groups [11].
Stockholm III trial compared short-course radiotherapy (5
× 5 Gy) with long-course radiotherapy (25 × 2 Gy) with-
out chemotherapy both with delayed surgery and reported
12.5% complete response rate after short-course RT com-
pared with 5% after long-course RT (P < 0.05) [12].
On the contrary, we found that complete response rate
was 4.4% after RT vs. 11.1% after CRT (P > 0.05) and
downstaging (pathological stage 0 and I) was observed in
30.9% cases in RT group vs. 37.5% cases in CRT group.
According to Stockholm III trial results, pathological stage
0 and I was found in 45% cases after short-course and in
30% cases after long-course RT. These differences could
be explained as follows: chemotherapy was added to long-
course radiotherapy according the protocol of our trial.
Disease progression was observed in 25% of cases in
RT group vs. 18.3% of cases in CRT group. The rate of
local recurrence between groups was: 3.1% of cases in
RT group vs 5.6% of cases in CRT group, respectively.
3 year overall survival was comparable between the
groups: 82.4% after CRT vs. 78% after RT, but disease-
free survival was significantly better after CRT (75.1%)
than after RT (59%).
Distant metastases (undetected preoperatively) were
found intraoperatively for 5 patients (6.7%) after short-
course radiotherapy and 3 (4%) patients after chemoradio-
therapy. These patients were excluded from the analysis of
long-term results. The question if this distant spread was
missed during primary investigation is open, because ab-
dominal ultrasound (not CT) as a routine method of in-
vestigation was used according our trial protocol, but it
could also be the result of early cancer progression, and in
that case DFS would be slightly worse.
Local recurrence rate for resectable rectal cancer after
surgery with TME is quite low. The TME approach






Death 17 (25) 14 (19.4) 0.429
related to cancer 12 12
not related to cancer 3 0
unknown 2 2
Progression of rectal cancer 16 (25) 13 (18.3) 0.345
local recurrence alone 0 3 (4.2)
distant metastases alone 12 (18.8) 8 (11.3)
local recurrence with distant metastases
in liver and lungs 2 (3.1) 1 (1.4)
metastatic tumor in peritoneal cavity 2 (3.1) 1 (1.4)
Fig. 2 Overall and disease free survival rates for the trial patients according to treatment received
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increases the likelihood of clear circumferential resection
margins which corresponds to decreased rates of pelvic
recurrence [15]. The majority of rectal cancer deaths is
likely to be associated with distant metastases, not from
local recurrence. This could explain why no survival
benefit was found in the majority of trials comparing
various regimens of neoadjuvant treatment for rectal
cancer [2]. Chemotherapy controlling distant progression
of the disease could be beneficial for these patients, but
FFCD study did not prove any advantage for the addition
of 5-Fu to RT in terms of DFS or OS [7].
There is no discussion that low-risk rectal cancer pa-
tients for whom imaging allows safe R0 resection
should go for initial surgical treatment, while preopera-
tive chemoradiotherapy should be administered for pa-
tients with high risk of local recurrence (threatened
resection margins), [16]. A major concern is a large
group of patients with intermediate-risk rectal cancer
(T3, >3 mm CRM), for whom neoadjuvant chemoradio-
therapy appears to be potential overtreatment, but pre-
operative systemic chemotherapy controlling distant
spread could be beneficial. A pilot trial from Memorial
Sloan Kettering Cancer Center reported promising re-
sults of selective use of chemoradiation for patients
with intermediate-risk rectal cancer. Results from this
pilot study served as a background to initiate the
currently undergoing PROSPECT trial [16].
Despite discussions most authors agree that careful sta-
ging and individualized treatment approach including se-
lective combination of surgery, chemo- or radiotherapy,
should be recommended for patients with rectal cancer.
Conclusion
According to the results of the randomized controlled
trial, 3-years DFS was better in CRT group compared with
RT group with no difference in OS. Surgical recovery and
perioperative morbidity were similar between the groups.
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